Skip to main content
Equibles
HCAT logo

HCAT · Health Catalyst, Inc.

Track HCAT — free

Use HCAT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about HCAT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.59 +0.00 (+0.00%)
Rebalance outlook locked
Market Cap
$119.66M
Shares
75.26M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.59 Open$1.59 Day$1.59–1.65 52W close$1.00–3.69 Avg vol 30d816K Short int2.3M · 3.0% float · 1.6d Short vol48% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Oct 27, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Strong Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.5 · calm Equity put/call 0.39
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −16%
      below
      Price vs 50-day avg −19%
      below
      RSI (14) 36
      neutral
      MACD trend Negative
      52-week position 22%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −24%
      trailing
      6-month return −18%
      trailing
      YTD return −33%
      this year
      Relative strength −33%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 50d above 200d
      Institutional flow Distributing
      -3% holders QoQ · +34 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.04% of float · ▼ -23.3% MoM · 1.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      129 holders — near 3-yr low, contrarian setup
      Squeeze score 36
      low risk · 0–100
      Fundamentals
      Weak
      Revenue growth +1%
      Y/Y
      EPS growth −122%
      Y/Y
      Free cash flow $-237.0K
      Buyback $24.8M
      remaining
      Balance sheet $102.4M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 90%
      annualized · 1-yr
      Max drawdown −73%
      past year
      ATR 7.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 8 of last 8
      Latest guidance · from the 8-K filed Aug 6, 2026
      third quarter of 2026
      Total revenue Initiated $55M – $56M
      prior qtr $70.49M midpoint −21.3% QoQ
      Adjusted EBITDA Initiated $0 – $500,000
      full year of 2026
      Total revenue Lowered $246M – $249M
      May 11, 2026 $260M – $265M changed to Aug 6, 2026 $246M – $249M
      prior FY $311.14M midpoint −20.5% Y/Y
      Adjusted EBITDA Lowered $18M – $18.5M
      May 11, 2026 $30M – $33M changed to Aug 6, 2026 $18M – $18.5M
      Prior guidance period ended · from the 8-K filed May 11, 2026
      Total revenue · second quarter of 2026 $68M – $70M
      Adjusted EBITDA · second quarter of 2026 $9M – $10M
      Guided vs delivered · last 8 settled
      Total revenue second quarter of 2026
      guided $68M – $70M
      $70.49M Beat +2.2%
      Total revenue fourth quarter of 2025
      guided $73.5M
      $74.68M Beat +1.6%
      Total revenue full year of 2025
      guided $310M
      $311.14M Beat +0.4%
      Total Revenue Q3 2025
      guided $75M
      $76.32M Beat +1.8%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 4 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −16% Bearish
      Price vs 50-day avg
      −19% Bearish
      RSI (14)
      36 Neutral
      MACD trend
      Negative Bearish
      52-week position
      22% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 50d above 200d
      Institutional flow Distributing
      -3% holders QoQ · +34 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.04% of float · ▼ -23.3% MoM · 1.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      129 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      Range low $1 Now $2 · 22% Range high $4
      vs 200-day avg -16% vs 50-day avg -19%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted Net Income per share, basic and diluted non-GAAP $0.04 Three Months Ended June 30, 2026 —
      Vitalware Adjusted EBITDA non-GAAP 11.36M Six Months Ended June 30, 2026 —
      Platform Clients 162 As of December 31, 2025 —
      Dollar-Based Retention Rate (Tech + TEMS) 93% FY2025 —
      Net new Platform Clients 32 FY2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Health Information Services — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      HCAT
      Health Catalyst, Inc.
      this stock
      		$119.66M -33.5% +1.5% — 3.0%
      VEEV
      Veeva Systems Inc
      		 $39.78B +26.4% +28.1% 40.2 3.6%
      PMDIY
      Pro Medicus Ltd./ADR
      		 $13.02B -24.9% — — 0.0%
      BTSG
      BrightSpring Health Services, Inc.
      		 $12.25B +62.6% +28.2% 37.5 4.5%
      TEM
      Tempus AI, Inc.
      		 $11.56B +19.7% +83.4% — 16.6%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      129
      % held
      74.8%
      Net QoQ
      -3.1M sh
      Top holder
      First Light Asset Managem…
      Held Float
      View
      Held by Funds
      Fund positions
      90
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      2.3M
      Days to cover
      1.6d
      Change
      -695.9K sh
      View
      Short Volume
      Short vol %
      48%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      717
      Value
      $1.5K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      32.8%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $311.1M
      Net income (FY)
      $-178.0M
      EPS diluted
      $-2.55
      View
      Buybacks
      Authorized
      $40.0M
      Remaining
      $24.8M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      17
      View
      Proposed Sales
      Value
      $130.2K
      Shares
      70.5K
      Filed
      Mar 10, 2026
      View
      Exempt Offerings
      Offering
      $44.5M
      Filed
      Feb 6, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View
      Investor Relations
      Latest news
      Health Catalyst Reports Second Qu…
      Published
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      HCAT -2.5% -23.6% -18.5% -23.9% -33.5%
      SPY +1.1% +4.0% +14.7% +3.2% +13.1%
      vs SPY -3.6% -27.5% -33.1% -27.1% -46.6%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $40.00M
      Spent (derived)
      $15.20M
      Remaining
      $24.80M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1636422 CUSIP 42225T107 13F (30d) 109 filings 109 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)